Suppr超能文献

Wee激酶功能及多种小分子抑制剂使其失活的结构基础

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

作者信息

Zhu Jin-Yi, Cuellar Rebecca A, Berndt Norbert, Lee Hee Eun, Olesen Sanne H, Martin Mathew P, Jensen Jeffrey T, Georg Gunda I, Schönbrunn Ernst

机构信息

Drug Discovery Department, Moffitt Cancer Center , Tampa, Florida 33612, United States.

Department of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55414, United States.

出版信息

J Med Chem. 2017 Sep 28;60(18):7863-7875. doi: 10.1021/acs.jmedchem.7b00996. Epub 2017 Sep 14.

Abstract

Members of the Wee family of kinases negatively regulate the cell cycle via phosphorylation of CDK1 and are considered potential drug targets. Herein, we investigated the structure-function relationship of human Wee1, Wee2, and Myt1 (PKMYT1). Purified recombinant full-length proteins and kinase domain constructs differed substantially in phosphorylation states and catalytic competency, suggesting complex mechanisms of activation. A series of crystal structures reveal unique features that distinguish Wee1 and Wee2 from Myt1 and establish the structural basis of differential inhibition by the widely used Wee1 inhibitor MK-1775. Kinome profiling and cellular studies demonstrate that, in addition to Wee1 and Wee2, MK-1775 is an equally potent inhibitor of the polo-like kinase PLK1. Several previously unrecognized inhibitors of Wee kinases were discovered and characterized. Combined, the data provide a comprehensive view on the catalytic and structural properties of Wee kinases and a framework for the rational design of novel inhibitors thereof.

摘要

Wee激酶家族成员通过对细胞周期蛋白依赖性激酶1(CDK1)进行磷酸化来负调控细胞周期,被视为潜在的药物靶点。在此,我们研究了人类Wee1、Wee2和Myt1(PKMYT1)的结构-功能关系。纯化的重组全长蛋白和激酶结构域构建体在磷酸化状态和催化能力上存在显著差异,提示其激活机制复杂。一系列晶体结构揭示了Wee1和Wee2与Myt1不同的独特特征,并确立了广泛使用的Wee1抑制剂MK-1775产生差异抑制作用的结构基础。激酶组分析和细胞研究表明,除了Wee1和Wee2外,MK-1775还是polo样激酶PLK1的强效抑制剂。我们发现并表征了几种先前未被认识的Wee激酶抑制剂。综合来看,这些数据提供了关于Wee激酶催化和结构特性的全面视图,以及合理设计其新型抑制剂的框架。

相似文献

1
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
J Med Chem. 2017 Sep 28;60(18):7863-7875. doi: 10.1021/acs.jmedchem.7b00996. Epub 2017 Sep 14.
2
Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
Molecules. 2017 Nov 23;22(12):2045. doi: 10.3390/molecules22122045.
3
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.
4
Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
Cell Rep. 2015 Dec 22;13(11):2425-2439. doi: 10.1016/j.celrep.2015.11.021. Epub 2015 Dec 7.
5
Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
ChemMedChem. 2018 Aug 20;13(16):1681-1694. doi: 10.1002/cmdc.201800188. Epub 2018 Jul 11.
6
Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing.
J Biomol Struct Dyn. 2024 Nov;42(18):9337-9347. doi: 10.1080/07391102.2023.2251070. Epub 2023 Aug 26.
7
Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Cancer Res. 2019 Dec 1;79(23):5971-5985. doi: 10.1158/0008-5472.CAN-19-1961. Epub 2019 Oct 8.
8
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.
10
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Clin Cancer Res. 2017 Oct 15;23(20):6239-6253. doi: 10.1158/1078-0432.CCR-17-1284. Epub 2017 Jul 11.

引用本文的文献

2
Current progress in targeting mitotic kinases in PDAC.
RSC Med Chem. 2025 Jun 19. doi: 10.1039/d5md00162e.
3
PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.
Signal Transduct Target Ther. 2025 May 21;10(1):165. doi: 10.1038/s41392-025-02250-7.
6
Structure-based virtual screening discovers novel PKMYT1 inhibitors.
RSC Med Chem. 2024 Aug 6;15(9):3114-3124. doi: 10.1039/d4md00389f. eCollection 2024 Sep 19.
7
WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation.
Curr Cancer Drug Targets. 2025;25(4):370-385. doi: 10.2174/0115680096298370240520093003.
8
A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens.
Nat Struct Mol Biol. 2024 Mar;31(3):465-475. doi: 10.1038/s41594-024-01211-y. Epub 2024 Feb 5.
9
Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors.
Front Cell Dev Biol. 2023 Nov 2;11:1270542. doi: 10.3389/fcell.2023.1270542. eCollection 2023.
10
Oocyte-specific Wee1-like protein kinase 2 is dispensable for fertility in mice.
PLoS One. 2023 Aug 1;18(8):e0289083. doi: 10.1371/journal.pone.0289083. eCollection 2023.

本文引用的文献

1
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
ACS Chem Biol. 2017 Jul 21;12(7):1883-1892. doi: 10.1021/acschembio.7b00147. Epub 2017 Jun 7.
2
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
Cancer Chemother Pharmacol. 2017 Jun;79(6):1257-1265. doi: 10.1007/s00280-017-3303-z. Epub 2017 Apr 19.
4
Targeting WEE1 Kinase in Cancer.
Trends Pharmacol Sci. 2016 Oct;37(10):872-881. doi: 10.1016/j.tips.2016.06.006. Epub 2016 Jul 14.
5
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.
6
Discovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile20-like Kinase 3 (MST3).
ChemMedChem. 2016 Jun 6;11(11):1137-44. doi: 10.1002/cmdc.201600115. Epub 2016 May 2.
8
Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
Cell Rep. 2015 Dec 22;13(11):2425-2439. doi: 10.1016/j.celrep.2015.11.021. Epub 2015 Dec 7.
9
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
J Clin Oncol. 2015 Oct 20;33(30):3409-15. doi: 10.1200/JCO.2014.60.4009. Epub 2015 May 11.
10
Wee1 kinase as a target for cancer therapy.
Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验